Glaucoma Surgery Devices Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Global Glaucoma Surgery Devices Market Trends and Insights

Rising Prevalence of Glaucoma

New epidemiology indicates that 4.22 million U.S. adults carry a glaucoma diagnosis, equating to a 1.62% prevalence rate across adults aged 18 years or older ^{[1]Steven Mansberger et al., “Prevalence of Glaucoma in the United States,” JAMA Ophthalmology, jamanetwork.com} . In the United States, non-Hispanic Black adults show a 3.15% prevalence versus 1.42% among non-Hispanic White adults, pushing device makers to tailor outreach programs and design studies that reflect racially diverse disease patterns ^{[2]University of Michigan Kellogg Eye Center, “Racial Disparities in Glaucoma,” umich.edu} . Asia-Pacific shoulders almost 60% of global glaucoma cases, magnifying the urgency for affordable, high-volume surgical solutions. As incidence climbs, procurement officials in public hospitals view MIGS as a cost-effective option to lessen lifetime medication spend and improve long-term vision retention. This epidemiological pressure is reshaping the glaucoma surgery devices market as suppliers prioritize higher-burden regions for direct distribution and local manufacturing.

Increasing Geriatric Population

Worldwide, populations aged 65 years and above are expanding faster than any other cohort, and glaucoma incidence rises sharply beyond age 60. Developed nations already have infrastructure that supports advanced micro-devices, yet rapidly aging middle-income countries now encounter similar disease loads without comparable specialist density. Health systems acknowledge that moving patients to earlier surgical care mitigates the cumulative burden of topical therapy and follow-up visits, leading to policy shifts that elevate cataract-combined MIGS procedures ^{[3]Glaucoma Research Foundation, “Aging and Glaucoma,” glaucoma.org} . In geriatric eyes, minimally invasive implants produce fewer inflammatory complications than trabeculectomy, allowing quicker visual rehabilitation. The demographic swell therefore sustains procedure demand even in markets where adoption appeared saturated.

Growing Adoption of Surgical Treatments

Clinical evidence has repositioned surgical intervention as a first- or second-line strategy. The LIGHT trial proved selective laser trabeculoplasty superior to eye drops for newly diagnosed patients, spurring guideline revisions in Europe and North America. Medicare’s separate payment for standalone MIGS and laser procedures expanded surgeon willingness to intervene sooner, lifting case volumes in outpatient suites. Training curricula now embed MIGS into resident programs, lowering the technical barrier for widespread use. Automated devices like Alcon’s Voyager DSLT shorten learning curves by replacing manual aiming with algorithmic targeting, encouraging broader uptake in community ophthalmology centers. Collectively, these shifts translate into higher unit sales for state-of-the-art implants and lasers, underpinning steady growth in the glaucoma surgery devices market.

Accelerated Regulatory Approvals for Next-Gen MIGS

Regulators have signaled a receptive stance toward innovation. In February 2024, the FDA cleared Glaukos iStent Infinite, the first micro-stent approved for standalone implantation in refractory cases, marking a pivotal expansion beyond cataract-combined indications. Balance Ophthalmics secured De Novo classification for its pulse-modulated FSYX system only five months later, highlighting streamlined evaluation paths for novel mechanisms. Europe’s CE-mark timeline is narrowing as notified bodies prioritize ophthalmic devices, as seen with ViaLase’s femtosecond platform certified in July 2024. Insurance authorities are paralleling regulators: U.S. Medicare contractors finalized local coverage for multiple MIGS codes in November 2024, trimming payer friction for surgeons. Faster approvals directly shorten commercial ramp-up cycles, lifting revenue forecasts across the glaucoma surgery devices market.

Availability of Alternative Therapies

Innovations in pharmaceutical delivery and non-incisional lasers are slowing the referral of early-stage patients into the operating room. Sustained-release implants such as iDose TR deliver three-year prostaglandin analog therapy without an incision, and the LIGHT trial placed selective laser trabeculoplasty ahead of eye drops as a go-to initial therapy. Balance Ophthalmics’ FSYX platform posted 100% IOP response in pivotal data without breaching the eye wall, attracting clinicians wary of surgical risk. As these therapies lengthen the effective life of medical management, procedural growth could moderate unless surgical technologies continue to demonstrate superior long-term cost-effectiveness.

High Cost of Advanced Devices & Procedures

A complex MIGS kit may exceed USD 1,000 per eye, and capital equipment for automated lasers can surpass USD 200,000, excluding surgeon training costs. In low-resource markets, out-of-pocket payment deters uptake, even though the disease burden is high. Some hospitals adopt lower-priced drainage shunts like the Aurolab Aqueous Drainage Implant, yet global distribution remains spotty. Health insurers in emerging economies demand clearer proof of long-range savings before reimbursing premium implants, slowing broad diffusion of next-generation devices within the glaucoma surgery devices market.

Segment Analysis

By Product: Device Innovation Drives Market Differentiation

Glaucoma drainage devices secured a 40.12% share of the glaucoma surgery devices market in 2024, benefiting from decades of clinical familiarity and improved design features such as the valveless Ahmed ClearPath and the low-profile Paul implant. Laser systems, however, are forecast to grow at 6.92% CAGR through 2030 and are increasingly positioned as standalone first-line procedures. Alcon’s Voyager DSLT automates energy delivery, producing 62% medication-free outcomes at 12 months and lowering chair time, a crucial metric for high-volume centers. Drug-delivery implants, AI-assisted targeting tools, and adjustable shunts are entering clinical trials, signifying an expanding competitive canvas that should widen the glaucoma surgery devices market size for suppliers offering multiproduct portfolios.  

Surgeons continue to deploy traditional surgical instruments—forceps, scissors, and punches—because trabeculectomy remains mandatory for end-stage disease. Yet, even these tools are evolving; titanium tips reduce corneal haze and enable better visualization under high-definition microscope cameras, aligning with the broader theme of precision in the glaucoma surgery devices industry.

Note: Segment shares of all individual segments available upon report purchase

By Surgery Method: MIGS Dominance Accelerates Innovation Cycles

Minimally invasive glaucoma surgery held 47.23% of the glaucoma surgery devices market share in 2024. Patients favor its faster recovery and lower risk of hypotony. Laser surgery outpaces all other approaches, charting a 6.89% CAGR, led by selective laser trabeculoplasty and emerging femtosecond systems that promise non-incisional aqueous outflow enhancement. Schlemm’s canal-based devices, including the OMNI Surgical System from Sight Sciences, maintain durable IOP lowering at three-year follow-up, reinforcing clinician confidence.  

Traditional filtration surgery—trabeculectomy and tube shunts—remains critical for advanced or uncontrolled pressure cases. Suprachoroidal and subconjunctival implants are gathering evidence, positioning themselves as hybrid solutions between MIGS and traditional surgery. The interplay of these modalities ensures robust competition, sustaining device refresh cycles and protecting revenue diversity inside the glaucoma surgery devices market.

By End User: Ophthalmic Clinics Drive Market Expansion

Hospitals collectively managed 59.12% of glaucoma surgery procedures in 2024, but specialized ophthalmic clinics are emerging as growth leaders, clocking a 7.03% CAGR as they acquire MIGS-ready capital equipment. Clinics attract patients by offering shorter wait times, bundled cataract-plus-MIGS packages, and AI-enabled diagnostics that reduce the number of pre-op consultations. The glaucoma surgery devices market size attached to clinics thus grows alongside their capacity upgrades.  

Ambulatory surgery centers (ASCs) are the next frontier. Medicare parity has already sparked a wave of ASC certifications, and manufacturers now bundle instrument kits with in-service training, lowering the first-case barrier. Hospitals are responding by carving out dedicated glaucoma service lines to preserve referral streams in the glaucoma surgery devices industry.

Note: Segment shares of all individual segments available upon report purchase

By Glaucoma Type: Primary Glaucoma Dominance Shapes Product Development

Primary glaucoma comprised 80.14% of the glaucoma surgery devices market in 2024, dominated by open-angle disease that responds well to trabecular meshwork-targeted implants. Secondary glaucoma, while smaller, is expanding 6.98% annually as better imaging identifies steroid-induced, neovascular, and uveitic variants at earlier stages. Device developers are rewriting specifications to handle unique pathophysiology, such as anti-fibrotic coatings to resist inflammatory membranes in neovascular glaucoma.  

Angle-closure disease is challenging due to shallow chambers, yet MIGS devices with thinner profiles are entering trials. Normal-tension glaucoma, once managed solely with drops, now sees candidates for low-pressure-optimized shunts and pressure-sensing implants that fine-tune opening resistance in real time, supporting a nuanced expansion of the glaucoma surgery devices market.

Geography Analysis

North America generated 37.67% of global revenue in 2024, underpinned by comprehensive insurance coverage and a dense network of fellowship-trained surgeons. The United States remains the primary revenue engine, backed by Medicare’s separate payment pathway for standalone MIGS and ASC parity. Canada’s single-payer model reimburses implants based on provincial technology assessments, yielding moderate yet dependable adoption. Mexico’s private hospitals target medical tourists seeking combined cataract-MIGS procedures at competitive cash prices, adding incremental demand for cost-conscious devices.

Asia-Pacific delivers the fastest 7.14% CAGR, thanks to health-system modernization, rising disposable income, and a senior population boom. China’s tier-one hospitals now routinely stock second-generation MIGS, whereas tier-two facilities prefer lower-cost drainage tubes. India’s government insurance schemes are starting to reimburse basic stents, providing fertile ground for domestic OEMs that license Western IP. Japan and South Korea exhibit adoption curves akin to the United States, with clinics bundling AI-enabled diagnostics and micro-stents. Southeast Asian nations—Vietnam, Indonesia, and the Philippines—are training subspecialists through regional centers of excellence funded by industry grants, supporting future demand.

Europe exhibits steady mid-single-digit expansion as national health services introduce technology appraisal frameworks that reward procedures demonstrating long-term medication savings. Germany and the United Kingdom are early users of femtosecond laser trabeculotomy systems. France, Italy, and Spain invest in surgeon retraining programs that integrate MIGS into cataract fellowships. Eastern European markets, particularly Poland and Romania, are gradually opening to lower-priced implants as GDP per capita rises, broadening the addressable glaucoma surgery devices market.